Compare BigBearai Holdings Inc (BBAI) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs BioNTech SE - ADR — how do they compare? BigBearai Holdings Inc trades at $3.25 (market cap $1.60B), while BioNTech SE - ADR trades at $93.14 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 14.6× BigBearai Holdings Inc's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, BigBearai Holdings Inc nearer its low. Which is the better fit depends on your goals.
| BBAI | BNTX | |
|---|---|---|
Market Cap | $1.60B | $23.31B |
Sector | Technology | Health |
52-Week High | $8.91 | $119.34 |
52-Week Low | $2.61 | $83.89 |
Enterprise Value | $1.30B | $6.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BigBear.ai (BBAI) trades at $3.32, up 2.79% with a bullish technical signal. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations. Despite negative profitability metrics (-65.2% net margin), the stock shows institutional interest with 75% analyst hold ratings. Recent news highlights defense contract wins and generative AI platform expansion for Department of War missions.
Outlook remains cautious due to persistent losses and revenue headwinds, though backlog growth and government contracts provide stability. Investment opportunity exists in AI defense specialization, but risks include execution challenges and competitive pressure. The stock requires careful monitoring of profitability improvements and contract execution.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
